• About Us
• Pipeline
• Partnering
• Diseases
• Technology
• Investors
• News
• Careers
• Contact

• Strategy and Core Competencies
• Peptide Chemistry
• Publication List
• Patents

• Lixisenatide (Lyxumia®)
• ZP120
• Danegaptide
• Rotigaptide
• Elsiglutide
• ZP1848
• ZP2435
• ZP2929
• Miscellaneous
• By year

2009

Easton, J.A., Petersen, J.S., and Martin, P.E.M.
The Antiarrhythmic peptide AAP10 remodels Cx43 and Cx40 expression and function
Naunyn Schmiedebergs Arch Pharmacol, 2009, 380, 11-24

Piatnitski Chekler, E.L., Butera, J.A., Di, L., Swillo, R.E., Morgan, G.A., Rossman, E.I., Huselton, C., Larsen, B.D., Hennan, J.K.
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents
Bioorg.Med.Chem.Lett., 2009, 4551-4554

Petersen, Y.M., Skarbaliene, J., Christjansen, K., Björkenberg, B., Ebbenhoej, K. Larsen, K. Duelund, H., and Thorkildsen, C.:
Effective attenuation of small intestinal inflammation using a novel small intestinal mucosal enhancer: ZP1848.
Poster (P1012) at United European Gastroenterology Week 2009, UEGW/WCOG, 21-25 November 2009, London.
Gut, 2009, 58 (Suppl II), A308
Poster

Petersen, Y.M., Björkenberg, B., Hyttel, J., Knudsen, C.B., and Thorkildsen, C.:
Oral presentation (OP381) at United European Gastroenterology Week 2009, UEGW/WCOG, 21-25 November 2009, London
Gut, 2009, 58 (Suppl II), A80-A81
Presentation

Laurent, G., Leong-Poi, H., Mangat, I., Moe, G.W., Hu, X., So, P.P-S., Tarulli, E., Ramadeen, A., Rossman, E.I., Hennan, J.K., Dorian, P.:
Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs.
Circ Arrhythmia Electrophysiol. 2009, 2, 171-178

Spagnol, G., Coombs, W., Taffet. E.M., Larsen, B.D., Delmar, M. and Sorgen, P.L.:
Redefining the interaction domain of Cx43CT with RXP-E and Cx43CL: a story of synthetic peptide versus recombinantly expressed peptide.
Poster at at Internatinal Gap Junction Conference, Sedona, Arizona, 25-30 July 2009

Verma, V., Larsen, B.D., Coombs, W., Lin, X., Spagnol, G., Sorgen, P., Taffet, S. and Delmar, M.:Novel pharmacophores of connexin 43 based on the “RXP” series of Cx43-binding peptides.
Presentation at Internatinal Gap Junction Conference, Sedona, Arizona, 25-30 July 2009

Petersen, Y.M. Björkenberg,B., Christjansen, K.,  Stahlhut, M., Pedersen, H.D.,  and  Thorkildsen, C.:
Is the murine dextran sodium sulfate-induced colitis model valid for predicting drug efficacy in IBD
American Gastroenterological Association- Digestive Diseases Week 2009.Chicago, USA, May 30 to June 4, 2009
Abstract
Presentation

Christensen, M., Knop, F.K., Holst, J.J. and Vilsbøll, T.:
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
IDrugs 2009, 12, 503-513

Verma, V., Larsen, B.D., Coombs, W., Lin, X., Spagnol, G., Sorgen, P.L.,  Taffet, S.M., and Delmar, M.:
Novel Pharmacophores of Connexin43 Based on the “RXP” Series of Cx43-Binding Peptides
Circ Res. 2009, 105, 176-184

Rossman, E.I., Liu, K., Morgan, G.A., Swillo, R.E., Krueger, J.A., Gardell, S.J.,  Butera, J., Gruver, M., Kantrowitz, J., Feldman, H.S., Petersen, J.S., Haugan, K. and Hennan, J.K.:
The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
J. Pharmacol. Exp. Ther. 2009, 329, 1127-1133

Butera, J.A., Larsen, B.D., Hennan, J.K., Kerns, E., Di. L., Alimardanov, A., Swillo, R.E., Morgan, G.A., Liu, K., Wang, Q., Rossman, E.I., Unwalla, R. McDonald, L., Huselton, C., Petersen, J.S.:
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation.
J Med Chen, 2009, 52, 908-911

van Deurs, U.S.K., Hadrup, N., Petersen, J.S., Christensen, S., and  Jonassen, T.E.N.:
Nociceptin/orphanin FQ peptide receptor agonist Ac-RYYRWKKKKKKK-NH2 (ZP120) induces antinatriuresis in rats by stimulation of amiloride-sensitive sodium reabsorption.
J Pharmacol Exp Ther, 2009, 328, 533-539

Knudsen, C.B. and Jensen, A.L:
Development of an immunoaffinity purification sample preparation method prior to LC/MS/(MS) analysis for identification of peptide metabolites.
Hepatocyte Users Symposium 2009, Snekkersten, 22-23 January 2009. Abstract P5.
Poster

Fischetti, C., Rizzi, A. Gavioli, E.C., Marzola, G., Trapella, C., Guerrini, R.,  Petersen, J.S., and Calo, G.:
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
Peptides, 2009, 30, 248-255 

Home   Legal Disclaimer   Updated: 31.1.2012